Fennec Pharmaceuticals Inc. FENC 深 滬
等待開盤 08-10 09:30:00 美东时间
11.575
+0.735
+6.78%
華盛通- 最 高11.66
- 今 開10.99
- 成交量 22.67万股
- 最 低 10.99
- 昨 收 10.84
- 總市值 40.21万
- 52周最高 11.66
- 市盈率 靜 --
- 換手率 0.65%
- 52周最低 5.65
- 委 比 38.24%
- 總股本 3.47万
- 歷史最高 14.986
- 量 比 1.76
- 振 幅 6.18%
- 歷史最低 3.255
- 每 手 1
- 風險率 1.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
Fennec Pharmaceuticals Inc. will release its Q2 2026 financial results on August 11, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 a.m. Eastern Time. Details and registration links are available on the company’s website. Fennec, focused on reducing cisplatin-induced ototoxicity in cancer patients, commercializes PEDMARK®/PEDMARQSI®, approved in the U.S., Europe, and the U.K. The company has an exclusiv...
08-05 11:01
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fennec Pharmaceuticals Inc. granted 10,000 incentive stock options to a new non-executive employee under its 2026 Equity Inducement Plan. The options, exercisable at $9.00 per share, vest over three years and expire in ten years. Fennec focuses on reducing cisplatin-induced ototoxicity in cancer patients with its FDA-approved PEDMARK®. The company has partnered with Norgine to commercialize PEDMARQSI® in Europe and other regions.
06-15 10:00
HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $16
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $13 to $16.
05-22 18:49
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
Fennec Pharmaceuticals announced new research on PEDMARK® (sodium thiosulfate injection) at the 2026 ASCO Annual Meeting, showcasing its potential benefits for broader patient populations, including adolescents, adults, and those with head and neck cancers. Four independent studies highlight PEDMARK's safety, efficacy, and feasibility in reducing cisplatin-induced ototoxicity without compromising antitumor activity. Results demonstrate significan...
05-21 22:01
美股牛股 | 股价狂飙超68%！AI芯片新星Cerebras首日表现惊艳；光通信牛股POET涨超43%
股价狂飙超68%！AI芯片新星Cerebras首日表现惊艳；光通信牛股POET涨超43%，此前披露光引擎采购大单；无人机公司ONDS涨逾26%，Q1营收同比暴增逾十倍>>
05-15 19:10
Fennec Pharmaceuticals shares are trading higher. The company reported Q1 financial results.
Fennec Pharmaceuticals shares are trading higher. The company reported Q1 finan...
05-15 03:30
Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Fennec Pharmaceuticals (NASDAQ:FENC) released first-quarter financial results a...
05-14 21:32
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
